conditions
Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations
Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy
Galapagos Reconsiders Company Split After Market Developments
Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions
FDA’s Operation Warp Speed for Rare Diseases: First Five Participants Announced
FDA, Operation Warp Speed, Rare Diseases, START Program, Gene Therapies, Neurodegenerative Conditions